Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

Rhea-AI Summary

Acrivon Therapeutics, a clinical stage biopharmaceutical company, announced that CEO Peter Blume-Jensen will present an overview on March 13, 2023, at 3:20 p.m. ET during the Oppenheimer 33rd Annual Healthcare Conference. The presentation will be accessible via a live webcast on Acrivon's website. Acrivon focuses on developing precision oncology medicines using its proprietary AP3 platform, identifying patients whose tumors are sensitive to specific treatments. The company is advancing its lead candidate, ACR-368, a selective inhibitor targeting CHK1 and CHK2, in a Phase 2 trial across various tumor types. Acrivon’s OncoSignature companion diagnostics are in development to optimize patient treatment.

WATERTOWN, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced the company’s chief executive officer and president, Peter Blume-Jensen, M.D., Ph.D., will present a company overview on Monday, March 13, 2023 at 3:20 p.m. ET at the Oppenheimer 33^rd Annual Healthcare Conference taking place virtually.

To access the live webcast of this presentation, visit the Events & Presentations page within the investor section of the company’s website at https://ir.acrivon.com/news-events/events-presentations. A replay of the webcast will be available via the same link for 90 days following the event.

About Acrivon Therapeutics
Acrivon is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon’s proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics, or AP3. The AP3 platform enables the creation of drug-specific proprietary OncoSignature^® companion diagnostics that are used to identify the patients most likely to benefit from Acrivon’s drug candidates. Acrivon is currently advancing its lead candidate, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial across multiple tumor types. Acrivon’s ACR-368 OncoSignature^® test, which has not yet obtained regulatory approval, has been extensively evaluated in preclinical studies, including in two separate, blinded, prospectively-designed studies on pretreatment tumor biopsies collected from past third party Phase 2 trials in patients with ovarian cancer treated with ACR-368. In addition to ACR-368, Acrivon is also leveraging its proprietary AP3 precision medicine platform for developing its internally-discovered preclinical stage pipeline programs targeting two critical nodes in the DNA Damage Response, or DDR, including WEE1, a protein serine/threonine kinase, and the closely related PKMYT1.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Acrivon’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” set forth in Part II, Item 1A of the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on December 15, 2022 and in our other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Acrivon undertakes no duty to update such information except as required under applicable law.

Investor and Media Contacts:
Alexandra Santos
asantos@wheelhouselsa.com

Aljanae Reynolds
areynolds@wheelhouselsa.com

FAQ

When will Acrivon Therapeutics present at the Oppenheimer 33rd Annual Healthcare Conference?

Acrivon Therapeutics will present on March 13, 2023, at 3:20 p.m. ET.

How can I access the Acrivon Therapeutics presentation?

The presentation can be accessed via a live webcast on Acrivon's Events & Presentations page.

What is the focus of Acrivon Therapeutics?

Acrivon Therapeutics focuses on developing precision oncology medicines tailored to patients' tumor sensitivities.

What is ACR-368 and its status in clinical trials?

ACR-368 is Acrivon's lead candidate, currently in a potentially registrational Phase 2 trial targeting CHK1 and CHK2.

What is the AP3 platform developed by Acrivon Therapeutics?

The AP3 platform is Acrivon’s proprietary proteomics-based patient responder identification system for precision oncology.